Enochian Biosciences Inc. is on track to file an IND application for its innovative cancer platform around the early part or middle of next year. If successful, that would allow clinical trials to begin in the first half of next year.
Viome Life Sciences Inc. launched its Cancerdetect test for oral and throat cancer, the first in a developing portfolio of tests that use mRNA technology and an artificial intelligence (AI)-driven platform. The saliva-based oral and throat cancer test demonstrated 95% specificity and 90% sensitivity in identifying these notoriously difficult to diagnose malignancies in a recent study.
A recently published study demonstrated that Viome Life Science Inc.’s metatranscriptomic signature for oral cancer identified the malignancy from samples of saliva with more than 90% accuracy. The mRNA platform received breakthrough device designation from the FDA in May for both early-stage oral squamous cell carcinoma and oropharyngeal cancer.
LONDON - Ona Therapeutics SL has raised €30 million (US$33.9 million) in a series A round, providing the means to advance a new method of treating metastases by blocking the lipid metabolism of cancer cells.